Antiandrogen effects in models of androgen responsive cancer.
The ability of antiandrogens to antagonize androgen effects in androgen responsive tissues is well established. Antiandrogens may diminish in vivo or in vitro proliferation of some androgen responsive cancer cells without causing cessation of multiplication. These model studies are representative of clinical experience in treatment of human prostate cancer with antiandrogen therapy. Recent studies in the AXC/SSh rat prostate cancer model show that these cancer cells elaborate polypeptide growth factors which stimulate their proliferation. If growth factor production by these cells is androgen independent, this may provide an explanation for failure of androgen ablation or antiandrogen treatment to effectively halt prostate cancer cell proliferation.
Shain
S A
SA
Department of Cellular and Molecular Biology, Southwest Foundation for Biomedical Research, San Antonio, TX 78284.
Huot
R I
RI
D000726:Androgen Antagonists / Q000378:metabolism / Q000627:therapeutic use*; D000818:Animals; D002455:Cell Division / Q000187:drug effects; D008297:Male; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy; D009374:Neoplasms, Experimental / Q000188:drug therapy*; D009929:Organ Size / Q000187:drug effects; D011467:Prostate / Q000033:anatomy & histology; D011471:Prostatic Neoplasms / Q000188:drug therapy; D051381:Rats; D011944:Receptors, Androgen / Q000378:metabolism; D013739:Testosterone / Q000097:blood; D014407:Tumor Cells, Cultured
D000726:Androgen Antagonists; D011944:Receptors, Androgen; D013739:Testosterone